Systech International
Comprehensive identification and traceability platform.
Est 1985|Raised $7.5M
Comprehensive identification and traceability platform.
Published Aug 26, 2026
| Starting Price | Not publicly listed (quote-based); a third-party report cited published annual pricing | Quote-based / depends on offering; historically had various commercial programs | Quote-based (request pricing) |
| Best For | Pharmaceutical manufacturers/CDMOs needing EPCIS-based traceability, exception management, and optional non-additive barcode-based authentication | Organizations seeking a network-centric interoperability platform with extensive trading partner connections | Organizations seeking a broad portfolio spanning serialization, inspection, and traceability |
| Key Strength | Combined offering across serialization, traceability, and barcode-based authentication; corporate ownership under Dover/Markem-Imaje; SOC 2 Type II audit available on request | Large partner network and marketplace-style connectivity; documented partner ecosystem | Broad portfolio across hardware and software for traceability and inspection as part of Antares Vision Group |
| Key Weakness | Limited independent public review coverage on mainstream platforms; pricing is quote-based; public security documentation is limited beyond SOC 2 announcement | Complex pricing models and potential dependency on the network model for full value | Pricing and integration complexity can vary depending on module mix |
Systech’s differentiation is associated with:
TraceLink differentiates on network connectivity and pre-existing partner integrations; this can provide earlier connectivity value for organizations prioritizing partner coverage.
Antares Vision Group / rfxcel positions a combined hardware/software offering across inspection and traceability, which may suit buyers seeking a single-vendor ecosystem for hardware and software.
Market adoption statements found in public marketing (e.g., percentage-of-top companies claims) were vendor-originated; independent market-share reporting was not located in the accessible analyst sources during this research run.
Sources: